The first case in South China!

On the 11th, the operating room of the intervention center on the second floor of Building 4 of the First Affiliated Hospital of Jinan University (Guangzhou Overseas Chinese Hospital) began to get bus.

For malignant tumors, the introduction of safe and controllable radiopharmaceuticals into the tumor to destroy and kill the cancer cells is an effective solutio.

It is understood that the patient who received yttrium-90 treatment this time is a 48-year-old man with liver cance.

Zhang Yan introduced: "The patient was diagnosed with massive liver cancer in the right lobe of the liver, and the patient was more resistant to chemotherap.

After a multidisciplinary diagnosis and treatment team composed of experts and professors from the Department of Nuclear Medicine, Interventional Vascular Surgery, Hepatobiliary Surgery, Gastroenterology and other departments, after joint discussions with overseas supervisory experts, as well as full communication with patients and their families, the multidisciplinary diagnosis and treatment team believes that the patient is suitable for Treatment with yttrium [90Y] microsphere injectio.

In February this year, the National Cancer Center released the latest national cancer statistics, showing that there are 400,000 new cases of liver cancer in China every year, accounting for about 46% of new cases of liver cancer in the worl.

Eighty-five percent of patients lost the opportunity for surgery because the tumor was too large or had spread to distant site.

On January 30 this year, Yttrium 90 resin microsphere injection was officially approved for listing in Chin.